Citigroup’s ImmunityBio IBRX Stock Holding History

Citigroup’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$438K	Hold	50,000	–	–	﹤0.01%	3967
2026 Q1	$384K	Buy	+50,000	New	+$342K	﹤0.01%	3695

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup's IBRX Position: Q2 2026 in Review

Citigroup increased its ImmunityBio (IBRX) stake by 227% in Q2 2026, buying an estimated $2.89M and bringing the position to 550,276 shares worth $4.82M. The position accounts for ﹤0.01% of the portfolio, ranked #2172.

Citigroup first reported a position in IBRX in Q3 2015 and has held it in 44 quarters since. The position peaked at $8.17M in Q1 2025. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Citigroup held 550,276 shares of ImmunityBio worth $4.82M as of Q2 2026.
Citigroup bought 381,920 ImmunityBio shares in Q2 2026, an estimated $2.89M.
ImmunityBio made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2172 holding.
Citigroup first reported a position in ImmunityBio in Q3 2015 and has held it in 44 quarters since.
Citigroup's ImmunityBio position peaked at $8.17M in Q1 2025.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.